BeiGene, Ltd. (NASDAQ:BGNE) Shares Sold by Profund Advisors LLC

Profund Advisors LLC reduced its stake in shares of BeiGene, Ltd. (NASDAQ:BGNE) by 19.8% during the 2nd quarter, Holdings Channel.com reports. The fund owned 4,780 shares of the company’s stock after selling 1,181 shares during the quarter. Profund Advisors LLC’s holdings in BeiGene were worth $682,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Capital International Investors increased its position in shares of BeiGene by 11.5% during the first quarter. Capital International Investors now owns 7,064,428 shares of the company’s stock worth $1,104,806,000 after purchasing an additional 727,556 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in BeiGene by 6.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,026,094 shares of the company’s stock valued at $316,862,000 after buying an additional 117,905 shares during the last quarter. Capital International Inc. CA grew its position in shares of BeiGene by 6.0% during the first quarter. Capital International Inc. CA now owns 858,364 shares of the company’s stock worth $134,240,000 after acquiring an additional 48,615 shares during the last quarter. First Trust Advisors LP acquired a new position in shares of BeiGene in the 4th quarter valued at $39,632,000. Finally, Goldman Sachs Group Inc. raised its position in BeiGene by 175.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 214,339 shares of the company’s stock valued at $38,658,000 after purchasing an additional 136,458 shares during the last quarter. 48.55% of the stock is owned by hedge funds and other institutional investors.

BeiGene Price Performance

Shares of BGNE opened at $209.31 on Wednesday. The firm has a market capitalization of $20.28 billion, a PE ratio of -27.65 and a beta of 0.61. The stock’s 50 day moving average is $184.44 and its two-hundred day moving average is $165.15. BeiGene, Ltd. has a twelve month low of $126.97 and a twelve month high of $215.00. The company has a current ratio of 1.98, a quick ratio of 1.75 and a debt-to-equity ratio of 0.06.

BeiGene (NASDAQ:BGNE) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($1.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.27) by $1.12. The firm had revenue of $929.20 million for the quarter, compared to the consensus estimate of $810.34 million. BeiGene had a negative return on equity of 14.93% and a negative net margin of 16.91%. The company’s revenue for the quarter was up 56.1% compared to the same quarter last year. During the same period in the previous year, the business earned ($3.64) earnings per share. Research analysts anticipate that BeiGene, Ltd. will post -5.13 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. Bank of America lowered their price objective on shares of BeiGene from $180.00 to $152.50 and set a “neutral” rating on the stock in a research report on Tuesday, July 9th. Citigroup raised their price target on BeiGene from $269.00 to $288.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. JPMorgan Chase & Co. upped their price objective on BeiGene from $194.00 to $200.00 and gave the company an “overweight” rating in a research note on Tuesday, August 20th. Finally, JMP Securities started coverage on BeiGene in a research report on Wednesday, September 18th. They set a “market outperform” rating and a $288.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $241.21.

Insiders Place Their Bets

In other news, CFO Julia Aijun Wang sold 472 shares of the stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $143.90, for a total value of $67,920.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other BeiGene news, CFO Julia Aijun Wang sold 472 shares of the company’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $143.90, for a total transaction of $67,920.80. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Chan Henry Lee sold 834 shares of the stock in a transaction dated Tuesday, July 30th. The shares were sold at an average price of $160.57, for a total transaction of $133,915.38. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 11,999 shares of company stock worth $2,282,183. Corporate insiders own 7.43% of the company’s stock.

BeiGene Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.